<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201610317223N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-08-22</date_registration>
      <primary_sponsor>Royan Institute</primary_sponsor>
      <public_title>Comparison of fertilization percentage, embryo quality, implantation and pregnancy rate, between two sperm separation procedures in infertile men intra-cytoplasmic sperm injection candidate</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of fertilization percentage, embryo quality, pregnancy and implantation rate, between two sperm separation procedures (density gradient centrifugation with surface markers- density gradient centrifugation) in infertile men intra-cytoplasmic sperm injection candidate</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2015-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>113</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/7660</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Male factor infertility.</hc_freetext>
      <i_freetext>Intervention 1: In study group, total of oocytes were inseminated with sperm that selected with DGC following MACS processing (Separate intact spermatozoa from those that present apoptotic markers by magnetic particles conjugated with Annexin V, which has a high affinity for Phosphatidylserine)(MACS-DGC group). For MACS procedure, semen samples were washed twice with 1X buffer and diluted to ten million sperm per ml. Then, each semen sample was mixed with one hundred microliter of microbeads solution and then, this mixture was incubated for 15 min at room before being loaded to MACS column. Annexin positive sperm was retained within the column while annexin negative sperm were allowed to pass the column. Intervention 2: In control group (DGC group), oocytes were inseminated with sperm selected by Density gradient centrifugation method (based on viability and morphology). Density gradient centrifugation was prepared by laying 2 ml of 80% PureSperm into a sterile 15ml conical centrifuge tube. Then, 2 ml 40% PureSperm suspension was slowly layered over lower layer. Subsequently, semen sample were washed (5 min, 3000 rpm) with VitaSperm medium were overlayed on the 40% or upper layer. The layer was centrifuged for 20 min at 1000rpm. The supernatant was aspirated, pellet was resuspended, and washed twice with VitaSperm. &#13;
&#13;
After injection of sperm into the oocyte to embryo formation at day 3, events such as fertilization, cleavage and embryo formation occur that these phenomena are in vitro. After 3 days, embryos were transferred into the uterus and then assessed implantation and pregnancy in vivo condition.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Hossein Nasr-Esfahani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Royan Institute for Biotechnology, Royan St, Salman St, KHorasgan, Isfahan, Iran</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 31 9501 5688</telephone>
        <email>mh_nasr@med.mui.ac.ir</email>
        <affiliation>Royan Institute (Royan Institute for Biotechnology)</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Hossein Nasr-Esfahani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Royan Institute for Biotechnology, Royan St, Salman St, KHorasgan, Isfahan, Iran</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 31 9501 5688</telephone>
        <email>mh_nasr@med.mui.ac.ir</email>
        <affiliation>Royan Institute (Royan Institute for Biotechnology)</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Primary male factor infertility (according to the WHO-2010); with mean age of 20-45. &#13;
Exclusion criteria: Females factor infertility based on WHO criteria (2010); age higher than 35 years; less than 6 oocytes and poor quality oocyte</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>45 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N46</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Male infertility</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In study group, total of oocytes were inseminated with sperm that selected with DGC following MACS processing (Separate intact spermatozoa from those that present apoptotic markers by magnetic particles conjugated with Annexin V, which has a high affinity for Phosphatidylserine)(MACS-DGC group). For MACS procedure, semen samples were washed twice with 1X buffer and diluted to ten million sperm per ml. Then, each semen sample was mixed with one hundred microliter of microbeads solution and then, this mixture was incubated for 15 min at room before being loaded to MACS column. Annexin positive sperm was retained within the column while annexin negative sperm were allowed to pass the column.</i_keyword>
      <i_keyword>In control group (DGC group), oocytes were inseminated with sperm selected by Density gradient centrifugation method (based on viability and morphology). Density gradient centrifugation was prepared by laying 2 ml of 80% PureSperm into a sterile 15ml conical centrifuge tube. Then, 2 ml 40% PureSperm suspension was slowly layered over lower layer. Subsequently, semen sample were washed (5 min, 3000 rpm) with VitaSperm medium were overlayed on the 40% or upper layer. The layer was centrifuged for 20 min at 1000rpm. The supernatant was aspirated, pellet was resuspended, and washed twice with VitaSperm. &#13;
&#13;
After injection of sperm into the oocyte to embryo formation at day 3, events such as fertilization, cleavage and embryo formation occur that these phenomena are in vitro. After 3 days, embryos were transferred into the uterus and then assessed implantation and pregnancy in vivo condition.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fertilization rate. Timepoint: 16-18 h post insemination/injection. Method of measurement: View of 2 pronucleuse with invert microscope,the ratio of fertilized oocytes (2PN) by the total number of injected metaphase II oocytes, multiplied by 100.</prim_outcome>
      <prim_outcome>Implantation rate. Timepoint: 4 weeks after transfer. Method of measurement: The number of observed gestational sacs per number of transferred.</prim_outcome>
      <prim_outcome>Chemical pregnancy. Timepoint: 18 days post-ICSI. Method of measurement: Measurement of Beta HCG level in serum.</prim_outcome>
      <prim_outcome>Clinical pregnancy. Timepoint: 5 weeks after embryo transfer. Method of measurement: ultrasonography findings showing at least one embryo with a fetal heartbeat.</prim_outcome>
      <prim_outcome>Quality of embryo. Timepoint: On day 3 after oocyte retrieval. Method of measurement: Using a three-point scoring system including fragmentation rate, number of blastomere, shape and size.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Perinatal mortality ( fetal or neonatal death). Timepoint: At 20 completed weeks of gestational age and later, during childbirth, or up to 7 completed days after birth. Method of measurement: Through ultrasound.</sec_outcome>
      <sec_outcome>Miscarriage (The spontaneous loss of a clinical pregnancy ). Timepoint: Before 20 completed weeks of gestational age (18 weeks after fertilization). Method of measurement: Through ultrasound.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Isfahan Fertility and Infertility</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Royan Institute</source_name>
      <source_name>Isfahan Fertility and Infertility</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-01-07</approval_date>
        <contact_name>Ethical Committee of Royan Institute</contact_name>
        <contact_address>Royan Institute, Banihashem St, Resalat Ave, Tehran, Iran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
